Developer docs
API playgroundTry for free, no card

Search company profiles

Evariste

Full company profile

uuid0002ks5

Namestring
Evariste
Legal namestring
Evariste Ltd
Websiteurl
evariste.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Evariste is a London-based TechBio company that applies its AI-enabled drug discovery platform, Frobenius, to identify novel synthetic lethal targets in oncology and design small molecule therapeutics against them. The Frobenius platform combines machine learning, probabilistic modeling, and physics-based simulations, organized into two integrated modules: Frobenius Target, which analyzes multi-omic datasets to uncover synthetic lethal relationships and biomarkers, and Frobenius Discovery, which performs virtual screening, multi-parameter optimization, and free energy calculations to produce differentiated drug candidates. Distinctive technical components include Non-Equilibrium Switching (NES) free energy calculations, the Dynamic Pose Database (PoseDB), Bayesian uncertainty modeling that separates aleatoric and epistemic noise, and proprietary automated compound design algorithms producing on the order of 10^6 molecules per design cycle. Evariste's preclinical pipeline centers on a nominated PKMYT1 development candidate (EVT-3023), a VRK1 program for glioblastoma, and 10+ additional synthetic lethal programs across AML, DLBCL, NSCLC, CRC, ovarian, and other cancers.

Evariste operates a B2B partnership and licensing model rather than selling discrete products. Revenue streams take three forms: platform licensing and preclinical research agreements with pharmaceutical companies (exemplified by a December 2024 preclinical collaboration with Finland's Orion Corporation); licensing of pipeline assets such as EVT-3023; and collaborative research arrangements with academic institutions including the University of Southampton (for proprietary oesophageal adenocarcinoma datasets) and the Institute of Cancer Research. The company also leverages incubator and ecosystem programs such as the Servier Golden Ticket and NVIDIA Inception. Distribution is entirely through direct enterprise engagement; no standard pricing tiers are published. Customers are concentrated among large pharmaceutical companies seeking differentiated oncology targets and academic centers providing translational datasets and validation.

The company is privately held, was founded around 2017, and operates with a small team of 1-10 employees that is multidisciplinary across drug discovery, mathematics, and AI. Leadership includes CEO Anna Hercot, CSO Alfie Brennan (ex-Institute of Cancer Research), Head Quant Oliver Vipond (Oxford math PhD), and a scientific board that includes former AstraZeneca Tagrisso chemistry lead Mike Waring and ICR's Olivia Rossanese. Evariste is in the process of launching a second product line, Blaise AI, positioned as a next-generation AI tool for small molecule analysis.

Short descriptiontext

Evariste is a London-based TechBio company that uses its proprietary AI platform Frobenius to discover synthetic lethal oncology targets and design small molecule therapeutics, partnering with pharmaceutical companies and academic institutions on platform licensing and pipeline asset deals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, synthetic lethality oncology, small molecule therapeutics, computational biology platform, precision oncology pipeline
Industry3 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-Enabled Drug Discovery Platform
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Licensing and Collaboration Agreements
TypeLicensing Royalties
Description

Evariste licenses its Frobenius platform to pharmaceutical partners for drug discovery programs. Collaborations include preclinical research agreements where Evariste designs inhibitors for partner-selected targets using its full suite of ML algorithms and compound designers.

evariste.com
2Pipeline Asset Licensing
TypeLicensing Royalties
Description

The company seeks licensing deals for innovative pipeline assets, including development candidates like EVT-3023 PKMYT1 inhibitor and other preclinical programs targeting novel synthetic lethal targets.

evariste.com
3Collaborative Research and Development
TypeProfessional Services
Description

Strategic partnerships with pharmaceutical companies and academic institutions for joint discovery programs, combining Evariste's AI platform capabilities with partner resources and expertise.

evariste.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Blaise AI
Description

Next generation AI for small molecule analysis - launching product

evariste.com
+3 more records
Core offering1 text field

Evariste discovers novel synthetic lethal oncology targets and designs small molecule therapeutics using its AI-enabled Frobenius platform. The company operates two integrated platform modules — Frobenius Target for novel target and biomarker identification through multi-omic data analysis, and Frobenius Discovery for automated small molecule design and multi-parameter optimization. Evariste also develops an internal pipeline of precision oncology assets (including the EVT-3023 PKMYT1 inhibitor and a VRK1 inhibitor) that it licenses to pharmaceutical partners through preclinical research agreements and pipeline asset licensing deals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Achieved best-in-class potency and selectivity in fewer than 50 compounds, with roughly 10-fold potency increase for every 30 compounds tested
+4 more records
Product overview1 text field

Evariste is an AI-enabled drug discovery company offering a platform-based approach centered on the Frobenius AI drug discovery platform. The platform consists of two main integrated modules: Frobenius Target for identification of novel synthetic lethal targets and biomarkers through multi-omic data analysis, and Frobenius Discovery for small molecule drug design using virtual screening, machine learning-driven optimization, and physics-based simulations. The company also announced the launch of Blaise AI as the next generation of AI for small molecule analysis. ESA Scoring is an additional feature within Frobenius Discovery that automates synthetic accessibility assessment for compound prioritization.

Product and service5 records
1Frobenius
CategoryAI Drug Discovery Platform
Description

Evariste's AI-enabled drug discovery platform that integrates target identification, small molecule design, and optimization capabilities. Frobenius uses machine learning, probabilistic modeling, and physics-based simulations to discover and develop novel small molecule therapeutics targeting synthetic lethal pathways in oncology. The platform is licensed to pharmaceutical partners through preclinical research agreements.

2Blaise AI
CategoryAI Drug Discovery Platform
Description

Next-generation AI system for small molecule analysis, described as 'the next generation of AI for small molecule analysis'. It represents a new product launch extending Evariste's AI capabilities beyond the Frobenius platform.

3EVT-3023 (PKMYT1 inhibitor)
CategoryOncology Pipeline Asset
Description

Pipeline development candidate targeting PKMYT1, which drives synthetic lethality in cancer cells with high replication stress. EVT-3023 is well-tolerated and efficacious in multiple tumor models and shows best-in-class potency and selectivity over key off targets including WEE1 and the Raf family. Available for licensing to pharmaceutical partners.

4VRK1 inhibitor program
CategoryOncology Pipeline Asset
Description

Pipeline program targeting VRK1 inhibition, which is synthetic lethal with VRK2 under-expression. VRK1 is highly ranked as a target in glioblastoma and neuroblastoma. There are no clinical competitors for this target and Evariste has designed potent inhibitors optimized for CNS permeability. Available for licensing to pharmaceutical partners.

5Novel synthetic lethal target program (undisclosed)
CategoryOncology Pipeline Asset
Description

Pipeline program targeting an undisclosed metabolic enzyme for heavily pretreated hematological malignancies. The synthetic lethal target is present in a subset of acute myeloid leukemia and diffuse large B-cell lymphoma patients, as well as in HR-deficient solid tumors. Evariste has designed the first ever inhibitors for this target. Available for licensing to pharmaceutical partners.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-25
Description

Director of Drug Discovery and Head of Division for Cancer Therapeutics at ICR (Olivia Rossanese) serves on Evariste's Board of Directors. Formerly a member of GSK's Tafinlar discovery team with extensive experience in discovery and target validation programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-23
Description

Evariste won the Servier Golden Ticket award, receiving a year's residence at Spartners by Servier & BioLabs incubator at Servier's R&D Institute in Paris-Saclay. Provides access to shared fully-equipped laboratories, BioLabs network, Servier's state-of-the-art laboratories, mentorship from industry experts, and operational resources for therapeutic innovation development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-13
Description

Evariste partnered with the University of Southampton's School of Cancer Sciences to generate one of the largest clinically annotated transcriptomic datasets in oesophageal adenocarcinoma (OAC). Evariste applies its AI-driven discovery engine to identify novel therapeutic targets for OAC patients who currently have very few targeted treatment options.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-10
Description

Evariste entered into a preclinical research agreement with Orion Corporation, a leading Finnish pharmaceutical company. Under the agreement, Evariste uses its Frobenius Discovery platform to design small molecule inhibitors for a target selected by Orion. The collaboration deploys the full suite of proprietary ML algorithms, automated compound designers, and accelerated free energy calculations to deliver potential candidate molecules.

5OpenSource Malaria Project (Professor Mat Todd, UCL)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Evariste contributed to the OpenSource Malaria project coordinated by Professor Mat Todd at UCL. Used Frobenius platform to design and synthesize novel anti-malarial compounds. Project included automated library construction, ML-based scoring, and compound selection using pessimistic design algorithm.

evariste.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Evariste contributed to the Covid Moonshot project coordinated by PostEra, focused on identifying drugs targeting the SARS-CoV-2 main protease. Used Frobenius platform to generate novel compound designs and contribute to the open science drug discovery effort.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven precision medicine company focused on small molecule drug discovery using its proprietary Centaur AI platform. Comparable to Evariste in platform-based small molecule design with active pharma partnerships and pipeline assets, though more clinically advanced.

TypeDirect peer
Description

Synthetic lethality-focused oncology company with multiple clinical-stage programs and a platform approach to identifying novel SL targets. Direct peer to Evariste in the synthetic lethality space, especially around discovery of novel targets and biomarker-driven patient selection.

3Artios Pharma
TypeDirect peer
Description

DNA damage response and synthetic lethality company developing small molecule therapeutics in oncology. Comparable to Evariste on the synthetic lethal mechanism of action and on being a UK/European oncology platform with multiple programs.

TypeDirect peer
Description

AI-driven drug discovery company using deep learning, generative chemistry, and biology to identify targets and design molecules. Comparable platform-plus-pipeline model to Evariste with both internal pipeline and pharma collaborations; competes directly in the AI-enabled small molecule space.

5Iambic Therapeutics
TypeEmerging player
Description

AI-driven drug discovery company combining physics-based simulation with machine learning for clinical-stage small molecule design. Comparable to Evariste in technical approach (physics + ML for chemistry) and small molecule focus, but more clinically advanced.

TypeDirect peer
Description

AI-driven pharmaceutical technology company combining physics-based modeling, quantum chemistry, and ML for small molecule discovery. Comparable to Evariste in computational chemistry capabilities and in offering both platform services and internal pipeline assets.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel targets and small molecule candidates. Directly comparable to Evariste in using AI/ML to power target identification and chemistry, with a similar platform-plus-pipeline model in oncology and other therapeutic areas.

TypeDirect peer
Description

Precision oncology company developing synthetic lethal and DNA damage response (DDR) therapies, including a clinical-stage PKMYT1 inhibitor (RP-3467). Most directly comparable to Evariste on the synthetic lethality/PKMYT1 axis, and a benchmark for the value-creation potential of Evariste's lead asset.

TypeEmerging player
Description

AI platform for protein and small molecule design serving biotech and pharma partners. Comparable emerging player to Evariste in platform-based AI for early-stage drug discovery, though focused on protein engineering rather than synthetic lethal target identification.

10Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery company building on DeepMind's AlphaFold to discover and design new drugs. Comparable in using AI/ML and physics-based modeling for drug discovery, but with substantially greater resources and a broader therapeutic scope than Evariste.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evariste

AI-Enabled Drug Discovery Platformevariste.com

Evariste is a London-based TechBio company that uses its proprietary AI platform Frobenius to discover synthetic lethal oncology targets and design small molecule therapeutics, partnering with pharmaceutical companies and academic institutions on platform licensing and pipeline asset deals.

What Evariste does

Evariste is a London-based TechBio company that applies its AI-enabled drug discovery platform, Frobenius, to identify novel synthetic lethal targets in oncology and design small molecule therapeutics against them. The Frobenius platform combines machine learning, probabilistic modeling, and physics-based simulations, organized into two integrated modules: Frobenius Target, which analyzes multi-omic datasets to uncover synthetic lethal relationships and biomarkers, and Frobenius Discovery, which performs virtual screening, multi-parameter optimization, and free energy calculations to produce differentiated drug candidates. Distinctive technical components include Non-Equilibrium Switching (NES) free energy calculations, the Dynamic Pose Database (PoseDB), Bayesian uncertainty modeling that separates aleatoric and epistemic noise, and proprietary automated compound design algorithms producing on the order of 10^6 molecules per design cycle. Evariste's preclinical pipeline centers on a nominated PKMYT1 development candidate (EVT-3023), a VRK1 program for glioblastoma, and 10+ additional synthetic lethal programs across AML, DLBCL, NSCLC, CRC, ovarian, and other cancers.

Evariste operates a B2B partnership and licensing model rather than selling discrete products. Revenue streams take three forms: platform licensing and preclinical research agreements with pharmaceutical companies (exemplified by a December 2024 preclinical collaboration with Finland's Orion Corporation); licensing of pipeline assets such as EVT-3023; and collaborative research arrangements with academic institutions including the University of Southampton (for proprietary oesophageal adenocarcinoma datasets) and the Institute of Cancer Research. The company also leverages incubator and ecosystem programs such as the Servier Golden Ticket and NVIDIA Inception. Distribution is entirely through direct enterprise engagement; no standard pricing tiers are published. Customers are concentrated among large pharmaceutical companies seeking differentiated oncology targets and academic centers providing translational datasets and validation.

The company is privately held, was founded around 2017, and operates with a small team of 1-10 employees that is multidisciplinary across drug discovery, mathematics, and AI. Leadership includes CEO Anna Hercot, CSO Alfie Brennan (ex-Institute of Cancer Research), Head Quant Oliver Vipond (Oxford math PhD), and a scientific board that includes former AstraZeneca Tagrisso chemistry lead Mike Waring and ICR's Olivia Rossanese. Evariste is in the process of launching a second product line, Blaise AI, positioned as a next-generation AI tool for small molecule analysis.

Evariste firmographics

Firmographics
Name
Evariste
Legal name
Evariste Ltd
Website
https://evariste.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Evariste is a London-based TechBio company that uses its proprietary AI platform Frobenius to discover synthetic lethal oncology targets and design small molecule therapeutics, partnering with pharmaceutical companies and academic institutions on platform licensing and pipeline asset deals.
Ownership category
akta.pro rank

Evariste industry classification

Industry
Product category
AI-Enabled Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Synthetic lethality oncology
  • Small molecule therapeutics
  • Computational biology platform
  • Precision oncology pipeline

Where Evariste is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Evariste business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Platform Licensing and Collaboration Agreements: Evariste licenses its Frobenius platform to pharmaceutical partners for drug discovery programs. Collaborations include preclinical research agreements where Evariste designs inhibitors for partner-selected targets using its full suite of ML algorithms and compound designers.
  2. Pipeline Asset Licensing: The company seeks licensing deals for innovative pipeline assets, including development candidates like EVT-3023 PKMYT1 inhibitor and other preclinical programs targeting novel synthetic lethal targets.
  3. Collaborative Research and Development: Strategic partnerships with pharmaceutical companies and academic institutions for joint discovery programs, combining Evariste's AI platform capabilities with partner resources and expertise.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Evariste product offering

Product offering

Core offering

Evariste discovers novel synthetic lethal oncology targets and designs small molecule therapeutics using its AI-enabled Frobenius platform. The company operates two integrated platform modules — Frobenius Target for novel target and biomarker identification through multi-omic data analysis, and Frobenius Discovery for automated small molecule design and multi-parameter optimization. Evariste also develops an internal pipeline of precision oncology assets (including the EVT-3023 PKMYT1 inhibitor and a VRK1 inhibitor) that it licenses to pharmaceutical partners through preclinical research agreements and pipeline asset licensing deals.

Product overview

Evariste is an AI-enabled drug discovery company offering a platform-based approach centered on the Frobenius AI drug discovery platform. The platform consists of two main integrated modules: Frobenius Target for identification of novel synthetic lethal targets and biomarkers through multi-omic data analysis, and Frobenius Discovery for small molecule drug design using virtual screening, machine learning-driven optimization, and physics-based simulations. The company also announced the launch of Blaise AI as the next generation of AI for small molecule analysis. ESA Scoring is an additional feature within Frobenius Discovery that automates synthetic accessibility assessment for compound prioritization.

Differentiator

Problem solved

Functional benefit

Brands

  • Blaise AI: Next generation AI for small molecule analysis - launching product
  • Frobenius
  • Frobenius Target
  • Frobenius Discovery

Products and services

  • Frobenius Evariste's AI-enabled drug discovery platform that integrates target identification, small molecule design, and optimization capabilities. Frobenius uses machine learning, probabilistic modeling, and physics-based simulations to discover and develop novel small molecule therapeutics targeting synthetic lethal pathways in oncology. The platform is licensed to pharmaceutical partners through preclinical research agreements.
  • Blaise AI Next-generation AI system for small molecule analysis, described as 'the next generation of AI for small molecule analysis'. It represents a new product launch extending Evariste's AI capabilities beyond the Frobenius platform.
  • EVT-3023 (PKMYT1 inhibitor) Pipeline development candidate targeting PKMYT1, which drives synthetic lethality in cancer cells with high replication stress. EVT-3023 is well-tolerated and efficacious in multiple tumor models and shows best-in-class potency and selectivity over key off targets including WEE1 and the Raf family. Available for licensing to pharmaceutical partners.
  • VRK1 inhibitor program Pipeline program targeting VRK1 inhibition, which is synthetic lethal with VRK2 under-expression. VRK1 is highly ranked as a target in glioblastoma and neuroblastoma. There are no clinical competitors for this target and Evariste has designed potent inhibitors optimized for CNS permeability. Available for licensing to pharmaceutical partners.
  • Novel synthetic lethal target program (undisclosed) Pipeline program targeting an undisclosed metabolic enzyme for heavily pretreated hematological malignancies. The synthetic lethal target is present in a subset of acute myeloid leukemia and diffuse large B-cell lymphoma patients, as well as in HR-deficient solid tumors. Evariste has designed the first ever inhibitors for this target. Available for licensing to pharmaceutical partners.

Quantifiable outcome

  • Achieved best-in-class potency and selectivity in fewer than 50 compounds, with roughly 10-fold potency increase for every 30 compounds tested
  • +4 more outcomes

Companies that use Evariste

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Evariste technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature8 records

Evariste partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Institute of Cancer Research (ICR)coreStrategic or Co-development Partner · 25 April 2025Director of Drug Discovery and Head of Division for Cancer Therapeutics at ICR (Olivia Rossanese) serves on Evariste's Board of Directors. Formerly a member of GSK's Tafinlar discovery team with extensive experience in discovery and target validation programs.
  • Servier (Spartners by Servier & BioLabs)coreStrategic or Co-development Partner · 23 January 2025Evariste won the Servier Golden Ticket award, receiving a year's residence at Spartners by Servier & BioLabs incubator at Servier's R&D Institute in Paris-Saclay. Provides access to shared fully-equipped laboratories, BioLabs network, Servier's state-of-the-art laboratories, mentorship from industry experts, and operational resources for therapeutic innovation development.
  • University of SouthamptoncoreStrategic or Co-development Partner · 13 January 2025Evariste partnered with the University of Southampton's School of Cancer Sciences to generate one of the largest clinically annotated transcriptomic datasets in oesophageal adenocarcinoma (OAC). Evariste applies its AI-driven discovery engine to identify novel therapeutic targets for OAC patients who currently have very few targeted treatment options.
  • Orion CorporationcoreStrategic or Co-development Partner · 10 December 2024Evariste entered into a preclinical research agreement with Orion Corporation, a leading Finnish pharmaceutical company. Under the agreement, Evariste uses its Frobenius Discovery platform to design small molecule inhibitors for a target selected by Orion. The collaboration deploys the full suite of proprietary ML algorithms, automated compound designers, and accelerated free energy calculations to deliver potential candidate molecules.
  • OpenSource Malaria Project (Professor Mat Todd, UCL)minorStrategic or Co-development PartnerEvariste contributed to the OpenSource Malaria project coordinated by Professor Mat Todd at UCL. Used Frobenius platform to design and synthesize novel anti-malarial compounds. Project included automated library construction, ML-based scoring, and compound selection using pessimistic design algorithm.
  • PostEra (Covid Moonshot)minorStrategic or Co-development PartnerEvariste contributed to the Covid Moonshot project coordinated by PostEra, focused on identifying drugs targeting the SARS-CoV-2 main protease. Used Frobenius platform to generate novel compound designs and contribute to the open science drug discovery effort.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Evariste competitors and assessment

Company assessment

Direct peers

  • Exscientia: AI-driven precision medicine company focused on small molecule drug discovery using its proprietary Centaur AI platform. Comparable to Evariste in platform-based small molecule design with active pharma partnerships and pipeline assets, though more clinically advanced.
  • Tango Therapeutics: Synthetic lethality-focused oncology company with multiple clinical-stage programs and a platform approach to identifying novel SL targets. Direct peer to Evariste in the synthetic lethality space, especially around discovery of novel targets and biomarker-driven patient selection.
  • Artios Pharma: DNA damage response and synthetic lethality company developing small molecule therapeutics in oncology. Comparable to Evariste on the synthetic lethal mechanism of action and on being a UK/European oncology platform with multiple programs.
  • Insilico Medicine: AI-driven drug discovery company using deep learning, generative chemistry, and biology to identify targets and design molecules. Comparable platform-plus-pipeline model to Evariste with both internal pipeline and pharma collaborations; competes directly in the AI-enabled small molecule space.
  • XtalPi: AI-driven pharmaceutical technology company combining physics-based modeling, quantum chemistry, and ML for small molecule discovery. Comparable to Evariste in computational chemistry capabilities and in offering both platform services and internal pipeline assets.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel targets and small molecule candidates. Directly comparable to Evariste in using AI/ML to power target identification and chemistry, with a similar platform-plus-pipeline model in oncology and other therapeutic areas.
  • Repare Therapeutics: Precision oncology company developing synthetic lethal and DNA damage response (DDR) therapies, including a clinical-stage PKMYT1 inhibitor (RP-3467). Most directly comparable to Evariste on the synthetic lethality/PKMYT1 axis, and a benchmark for the value-creation potential of Evariste's lead asset.

Emerging players

  • Iambic Therapeutics: AI-driven drug discovery company combining physics-based simulation with machine learning for clinical-stage small molecule design. Comparable to Evariste in technical approach (physics + ML for chemistry) and small molecule focus, but more clinically advanced.
  • Cradle Bio: AI platform for protein and small molecule design serving biotech and pharma partners. Comparable emerging player to Evariste in platform-based AI for early-stage drug discovery, though focused on protein engineering rather than synthetic lethal target identification.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned AI drug discovery company building on DeepMind's AlphaFold to discover and design new drugs. Comparable in using AI/ML and physics-based modeling for drug discovery, but with substantially greater resources and a broader therapeutic scope than Evariste.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Evariste social profiles

Digital presence

Evariste financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evariste leadership team

Management profile

Number of profiles

Profiles17 records

Evariste funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evariste M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evariste

What does Evariste do?

Evariste discovers novel synthetic lethal oncology targets and designs small molecule therapeutics using its AI-enabled Frobenius platform. The company operates two integrated platform modules — Frobenius Target for novel target and biomarker identification through multi-omic data analysis, and Frobenius Discovery for automated small molecule design and multi-parameter optimization. Evariste also develops an internal pipeline of precision oncology assets (including the EVT-3023 PKMYT1 inhibitor and a VRK1 inhibitor) that it licenses to pharmaceutical partners through preclinical research agreements and pipeline asset licensing deals.

Is Evariste a public or private company?

Evariste is a private company. It is classified as venture growth investor backed and is currently operating.

When was Evariste founded?

Evariste was founded in 2017. It employs 1 to 10 people.

Where is Evariste based?

Evariste is headquartered in London, United Kingdom, in the Europe region.

How does Evariste make money?

Three revenue lines are on record. Platform Licensing and Collaboration Agreements are the primary driver. The others are pipeline Asset Licensing and collaborative Research and Development.

Who are Evariste's main competitors?

Direct peers on record are Exscientia, Tango Therapeutics, Artios Pharma, Insilico Medicine, XtalPi, Recursion Pharmaceuticals and Repare Therapeutics. Emerging players are Iambic Therapeutics and Cradle Bio. Isomorphic Labs is listed as a broad incumbent.

Does Evariste have an API?

No public API is recorded for Evariste.

What industry is Evariste in?

Evariste's product category is AI-Enabled Drug Discovery Platform. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals